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ABSTRACT 
Background/Aims: Evidence suggests Medicaid beneficiaries in the USA are prescribed 
opioids more frequently than are people who are privately-insured, but little is known about 
opioid prescribing patterns among Medicaid enrollees who gained coverage via the 
Affordable Care Act Medicaid expansions. This study compared the prevalence of receipt of 
opioid prescriptions and opioid-use-disorder (OUD), along with time from OUD diagnosis to 
medication-assisted treatment (MAT) receipt between Oregon residents who had been 
continuously insured by Medicaid, were newly insured after Medicaid expansion in 2014, or 
returned to Medicaid coverage after expansion. 
Design: Cross-sectional study using inverse-propensity weights to adjust for differences 
among insurance groups. 
Setting: Oregon. 
Participants: 225,295 Oregon Medicaid adult beneficiaries insured 2014-2015 and either: 1) 
newly enrolled, 2) returning in 2014 after a >12-month gap, or 3) continuously insured 
between 2013 and 2015. We excluded patients in hospice care or with cancer diagnoses. 
Measurements: Any opioid dispensed, chronic (≥90-day) and high dose (≥90 daily morphine 
milligram equivalence) opioid use, documented OUD diagnosis, and MAT receipt. 
Findings: Compared with the continuously insured, newly and returning insured enrollees 
were less likely to be dispensed opioids [newly: 42.3%, 95% confidence interval (95%CI) 
42.0-42.7%; returning: 49.3%, 95%CI 48.8-49.7%; continuously: 52.5%, 95%CI 52.0-
53.0%], use opioids chronically (newly: 12.8%, 95%CI 12.4-13.1%; returning: 11.9%, 
95%CI 11.5-12.3%, continuously: 15.8%, 95%CI 15.4-16.2%), have OUD diagnoses (newly: 
3.6%, 95%CI 3.4-3.7%; returning: 3.9%, 95%CI 3.8-4.1%, continuously: 4.7%, 95%CI 4.5-
4.9%), and receive MAT after OUD diagnosis [Hazard Ratio newly: 0.57, 95%CI 0.53-0.61; 
Hazard Ratio returning: 0.60, 95%CI 0.56-0.65 (REF: continuously)]. 
Conclusions: Residents of Oregon, USA who enrolled or re-enrolled in Medicaid health 
insurance after expansion of coverage in 2014 as a result of the Affordable Care Act were 
less likely than those already covered to receive opioids, use them chronically, or receive 
medication-assisted treatment for opioid use disorder. 
Keywords: Medicaid, Affordable Care Act, opioid epidemic, prescribed opioid use, opioid-
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INTRODUCTION AND CONTEXT 
Over the past 30 years, the role of long-term opioid therapy in managing chronic non-cancer 
pain has grown1, along with rates of opioid use disorder (OUD) among patients prescribed 
opioids2. By 2011, the United States (US) Office of National Drug Control Policy declared 
opioid prescription abuse an epidemic3. Data from the US National Survey on Drug Use and 
Health showed that in 2016, more than 34% of individuals age 12 and older had used opioids 
in the prior year4. In 2016, over 40,000 people died from an opioid overdose5. Oregon’s 
statistics mirror national trends: From 2009 to 2014, Oregon saw a sharp increase in opioid-
related inpatient hospitalizations6, and opioid-related overdose deaths in the state increased 
from 2,681 deaths (death rate: 2.1 per 100,000) in 2000 to 6,535 (6.5 per 100,000) in 20157. 
 
Before the 2014 Affordable Care Act (ACA) Medicaid expansion patients with Medicaid 
insurance were prescribed opioids at twice the rate of those without Medicaid8-9 and were on 
higher doses for longer periods of time10-11. Additionally, incidence of OUDs for Medicaid 
enrollees was about twice as high as in the general population12-13, with similar trends 
observed in the state of Oregon12. It is unknown, however, how opioid prescribing patterns 
differed between Medicaid enrollees who gained coverage from the 2014 ACA expansion 
and those who were previously eligible. Medicaid also provides access to medication-assisted 
treatment (MAT)13-15, which combines psychosocial therapy with Food and Drug 
Administration-approved medication. MAT is more effective in increasing treatment 
adherence in patients than either non-drug approaches16-17 or medication alone18, and 
Medicaid beneficiaries are more likely than privately-insured individuals to receive MAT14.  
 
As a state that experienced significant increases in Medicaid enrollment in 2014 and 2015 
(due to the ACA’s expansion of Medicaid coverage to non-disabled adults with incomes up to 
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138% of the federal poverty level)19 and one with increasing rates of OUD, Oregon is an 
excellent setting to examine opioid prescriptions and OUD treatment following the 2014 
Medicaid expansion. Prior research showed that, compared with individuals previously 
continuously insured under Medicaid, new beneficiaries used lower levels of healthcare 
services in 2014 and 201520. Furthermore, prior to the ACA expansion, the opioid epidemic 
had already attracted national attention in the US, and increasing awareness of the risks of 
opioid therapy may have influenced opioid prescribing patterns among new enrollees. 
 
The aim of this study was to compare the prevalence of opioid prescribing, the prevalence of 
OUD diagnosis, and time from OUD diagnosis to MAT treatment between three insurance 
groups (newly, returning, and continuously insured Oregon Medicaid enrollees) following the 
ACA Medicaid expansion. We also sought to understand the relationship between level of 
chronic and high dose opioid use and prevalence of OUD diagnosis in these insurance 
groups.  
 
METHODS: DATA AND MEASURES 
 
We obtained Oregon Medicaid enrollment (01/01/2002-12/31/2015) and administrative 
claims (01/01/2014-12/31/2015) data from the Oregon Health Authority that included both 
fee-for-service and managed care beneficiaries.  
 
Study Population: We included adults aged 19-64 continuously insured by Oregon Medicaid 
from January 1, 2014 through December 31, 2015. To capture changes in utilization among 
enrolled individuals rather than changes in enrollment, we excluded patients with any 
coverage gaps during the study period. We also excluded patients with dual Medicaid and 
Medicare eligibility (as we did not have access to Medicare data) and patients whose 2014-
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2015 eligibility was not related to the Medicaid expansion (e.g. pregnant women). Finally, we 
excluded those in hospice care or with a cancer diagnosis other than non-melanoma skin 
cancer because these patients often require intense, prolonged pain management21 and are 
exempt from the Centers for Disease Prevention and Control (CDC) opioid prescribing 
guidelines22. Of 622,513 adults aged 19-64 with any Medicaid enrollment in 2014, 225,295 
(36%) remained in our sample. See Appendix Exhibit A for a breakdown of exclusions. 
 
Insurance Groups: We categorized patients in our study sample as newly, returning, or 
continuously insured: 
1. Newly insured patients did not have any Medicaid coverage from 2002-2013 and had 
continuous coverage in 2014-2015; 
2. Returning insured patients had no Medicaid coverage in 2013, had Medicaid coverage 
sometime during 2002-2012 and had continuous coverage in 2014-2015; 
3. Continuously insured patients had Medicaid coverage for all of 2013 and continuous 
coverage in 2014-2015. 
 
Episodes of Opioid Prescribing: We grouped claims for each beneficiary into ‘episodes’ of 
consecutive opioid prescriptions. Prescriptions were considered consecutive if there was no 
more than a 30-day gap between the end of one and the start of another23. For each episode, 
we calculated its length, its total day supply, and its average daily dose measured in daily 
morphine milligram equivalents (MME). Episode length was the number of days between the 
date of the first claim in the episode and the date of the last plus the day supply of the last 
prescription. Total day supply was the day supply summed across all claims within the 
episode24-25. Average daily MME for an episode was determined by multiplying the quantity 
prescribed by the medication-specific strength times the conversion factor26, summing this 
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value for all prescriptions within the episode, and dividing by the total day supply. If total day 
supply was greater than episode length, suggesting multiple concurrent prescriptions, the 
denominator was truncated to episode length. All episodes of opioid prescribing were 
categorized as low (1-30 average daily MME), medium (31-90 average daily MME), or high 
(>90 average daily MME). The 30 daily MME threshold was chosen because it was the 
median prescribed daily dose across all episodes observed24. The 90 daily MME threshold 
was based on CDC guidelines, which generally recommend keeping dosages below this 
amount22. Other studies have chosen similar dose thresholds23-25. Finally, we summed the 
number of episodes experienced by each patient over the study period, operationalizing the 
sum as a categorical variable with 4 levels, representing 1, 2, 3, or 4+ prescribing episodes. 
 
Outcomes: To assess the prevalence of opioid prescribing and OUD diagnoses among 
Medicaid enrollees (full sample, n=225,295), we measured: 
1. Any opioid prescription filled: A binary variable indicating whether a subject filled 
any prescription from the CDC’s published list of opioids26 (excluding buprenorphine, 
a partial opioid agonist used for treatment of OUD in primary care settings27-28) 
during the study period. 
2. Documented diagnosis of OUD: A binary variable indicating whether a subject had a 
documented diagnosis of OUD, based on the presence of any international 
classification of diseases (ICD-9/10) codes for opioid abuse or dependence (Appendix 
Exhibit B1) in claims during the study period. 
 
We also estimated the prevalence of chronic opioid use and OUD among the subset 
(n=105,031) of Medicaid enrollees with any opioid prescription filled. We measured:  
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1. Any chronic opioid use: a binary variable indicating the presence of any chronic 
episode, with an episode considered chronic when its length was >90 days and the 
patient was dispensed >90 days’ supply during this period23-25,29. 
2. Level of chronic opioid use: a categorical variable with five levels: i) low/medium 
dose non-chronic use (≤90 average daily MME, ≤90 days); ii) high dose non-chronic 
use (>90 average daily MME, ≤90 days); iii) low dose chronic use (1-30 average 
daily MME, >90 days); iv) medium dose chronic use (31-90 average daily MME, 
>90 days), and v) high dose chronic use (>90 average daily MME, >90 days), with 
patients classified first based on their highest average dose chronic episode, then by 
whether they had any high dose use. 
3. Documented diagnosis of OUD. 
 
Among the subset of patients with OUD (n=8,637), we examined time to receipt of MAT 
services after OUD diagnosis. Receipt of MAT services was a binary variable indicating 
whether a subject had any procedure codes or pharmacy national drug codes indicating 
MAT30 (Appendix Exhibit B2) in claims during the study period. 
Independent Variables: The main independent variable was insurance group (defined above). 
When estimating OUD prevalence in patients with any opioid prescription, the independent 
variables were insurance group and episode type, representing both level of chronic use and 
whether they experienced a high dose episode. Episode type, a measure of length and 
intensity of prescribed opioid use, was operationalized as a categorical variable with the 
following five levels: 
1. Non-chronic use and no high dose; 
2. Low dose chronic use and no high dose; 
3. Non-chronic or low dose chronic use and at least one high dose; 
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4. Medium dose chronic use and no high dose; 
5. Medium or high dose chronic use and at least one high dose. 
 
Other Covariates: We adjusted for ‘number of episodes’ for all outcomes modeled in the 
sample of patients with any prescription (any chronic use, level of chronic use, and OUD 
prevalence).  
 
METHODS: STATISTICAL ANALYSES 
 
Propensity Score Weighting: To adjust for observable differences between the insurance 
groups that may have affected outcomes, we used inverse-probability of treatment weighting 
(IPTW)31 via the twang (toolkit for weighting and analysis of nonequivalent groups)32 
package in R (version 3.4.0), implementing a generalized boosted model that included the 
patient’s age, sex, racial and ethnic background, rural setting, zip-code-level poverty and 
unemployment percentiles, comorbidity level as assessed by the enhanced Charlson 
comorbidity index33, and diagnoses associated with chronic pain (see Appendix Exhibit B3 
for included pain categories and ICD-9/10 codes). We produced separate sets of average 
treatment effect weights for the full sample, the subset of patients with any opioid 
prescription, and the subset with OUD. For each patient characteristic included in the 
propensity model, we calculated absolute standardized mean differences between insurance 
groups before and after weighting to assess propensity score performance; standardized 
differences of less than 0.10 suggest good balance34. For all data sets, we estimated effective 
sample sizes (ESS), the approximate number of observations under simple random sampling 
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Parameter Estimates and Confidence Intervals (CIs): The following analyses were 
performed in Stata 15.1. We report point estimates and 95% CIs on all IPTW-adjusted 
parameter estimates (Appendix Exhibits D1-D7) from the proposed models below. 
 
Binary Logistic Regressions: Among the full sample, we ran IPTW binary logistic 
regressions to estimate the likelihood of having any opioid prescription filled and OUD 
diagnosis prevalence by insurance group. Among the subset of patients with any opioid 
prescription, we estimated the likelihood of having any chronic episode by insurance group, 
adjusted for number of episodes, as well as OUD diagnosis prevalence by insurance group 
and episode type, also adjusted for number of episodes. 
 
Multinomial Logistic Regression: We ran an IPTW multinomial logistic regression to 
predict the level of chronic use (low/medium dose non-chronic use, high dose non-chronic 
use, low dose chronic use, medium dose chronic use, or high dose chronic use) in patients 
with any opioid prescription by insurance group, adjusted for number of episodes. 
  
Cox Regression: Among the subset of patients with OUD diagnosis, we used an IPTW Cox 
proportional hazards model to examine the relationship between insurance group and time 
from OUD diagnosis to MAT. For this model, we excluded patients whose MAT receipt 
occurred before their first OUD diagnosis during the study period, as we were unable to 
determine their initial date of diagnosis (3.6% of patients with OUD).  
 
Additional Analyses: To address concerns of selection bias due to opioid-related deaths 
among the full sample, we assessed the likelihood of having experienced an overdose event 
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(binary), as indicated by ICD-9/10 codes (Appendix Exhibit B4) in study period claims by 




Covariate Balance between the Insurance Groups 
Full sample: Prior to weighting, the insurance groups differed on multiple demographic 
characteristics. Compared to returning and continuously insured enrollees, newly insured 
enrollees were more likely to be older, male, and Hispanic, live in an urban location, have 
fewer comorbidities and chronic pain-related diagnoses, and reside in zip codes with higher 
levels of poverty and unemployment. Balance improved for all covariates; ESS after 
weighting were as follows: 34,863 for continuously insured, 47,259 for returning insured, and 
86,957 for newly insured, for a total ESS of 169,079. For the distribution of covariates before 
and after weighting, see Table 1. 
 
Sample with any opioid dispensed: After weighting, balance improved for all covariates and 
the ESS were as follows: 25,832 for continuously insured, 27,607 for returning insured, and 
31,332 for newly insured. See Appendix Exhibit C1 for the distribution of covariates before 
and after weighting. Compared to the full sample, patients with opioid prescriptions were 
more likely to be older, female, and white, live in a rural location, have more comorbidities 
and chronic-pain related diagnoses, and reside in zip codes with higher levels of 
unemployment. 
 
Sample with OUD diagnosis: After weighting, balance improved for all covariates and the 
ESS were as follows: 2,550 for continuously insured, 2,515 for returning insured, and 2,327 
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for newly insured. See Appendix Exhibit C2 for the distribution of covariates before and after 
weighting. Compared to the full sample, patients with OUD diagnoses were more likely to be 
young, male, and white, live in an urban location, and have more comorbidities and chronic 
pain-related diagnoses.  
 
Outcomes 
Any opioid dispensed, any chronic opioid use, and level of chronic opioid use: Compared to 
the continuously insured, newly and returning insured enrollees were less likely to have any 
opioid dispensed, with newly insured less likely than returning insured (Table 2; Figure 1, x-
axis; Appendix D1). Among patients with opioid prescriptions, the newly insured were less 
likely than the continuously insured to be chronic users of all types (Table 2; Appendix D2) 
and less likely to be dispensed either a low, medium, or high daily chronic dose (Figure 1, y-
axis; Appendix D3).  
 
OUD diagnosis and time to receipt of MAT services: Among the full sample, the 
continuously insured were more likely than the newly and returning insured to have an OUD 
diagnosis, with newly insured less likely than returning insured (Table 2; Appendix D4). 
Among those with an OUD diagnosis, newly insured enrollees were 43% less likely to 
receive MAT after OUD diagnosis than the continuously insured. Similarly, the returning 
insured were 40% less likely to receive MAT after OUD diagnosis than the continuously 
insured, with no significant differences in MAT receipt observed between newly and 
returning insured (Table 2; Figure 2; Appendix D5). 
 
OUD diagnosis and episode type: Among those with any opioid dispensed, prevalence of 
OUD diagnosis for all insurance groups varied significantly by length and intensity of dose 
received during episodes. Generally, as length and intensity increased, so did prevalence of 
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OUD diagnosis. Patients with medium or high dose chronic use and at least one high dose 
were most likely to have an OUD diagnosis. Those with neither chronic use nor high dose 
episodes were least likely to have an OUD diagnosis (Figure 3; Appendix D6). 
 
Among those with any opioid dispensed, after adjusting for episode type, the newly and 
returning insured remained at lower odds of OUD diagnosis than the continuously insured 
(Table 2; Appendix D7).  
 
Additional analysis of overdose events: Among the full sample, less than half of a percent of 
patients with any prescribed opioid use experienced an overdose event. The continuously 
insured were slightly less likely than the newly and returning insured to have experienced an 
overdose event, with newly and returning insured similarly likely (Appendix D8). 
 
This study evaluated the relationship between insurance group (newly, returning and 
continuously insured enrollees) and opioid prescriptions, OUD diagnoses, and MAT receipt 
among Oregon Medicaid beneficiaries after the ACA Medicaid expansion. We found that 
42% of newly insured enrollees filled at least one prescription during the two-year study 
period, with estimates for returning (49%) and continuously insured enrollees (53%) 
reflecting even higher prevalences. 
 
Among those with opioid prescriptions, relative to the continuously insured, the newly and 
returning insured were less likely to be chronic opioid users. This suggests that policies to 
decrease opioid prescribing in recent years35 may be having their desired effect on the 
population of newly and returning Medicaid enrollees (in contrast with the continuously 
insured, who may face understandable difficulties in discontinuing long-term opioid therapy). 
However, differing levels of chronic and high dose opioid use may be, in part, a result of 
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unobserved differences in characteristics between the three groups that we were unable to 
control for. 
 
Confirming other studies24,37, we found prescribed dose and duration were both significant 
predictors of OUD diagnosis prevalence. Patients with medium or high dose chronic use and 
at least one high daily dose were roughly five times more likely to be diagnosed with OUD 
than those with neither chronic nor high daily dose use. Since the continuously insured were 
more likely to be dispensed higher doses for longer periods, the continuously insured were 
most likely to be diagnosed with OUD. But even after adjusting for the number of prescribing 
episodes and level of chronic and high dose use, the continuously insured were more likely 
than the newly or returning insured to have OUD diagnoses. This may be because 
continuously insured patients had more opportunities to receive diagnoses than new enrollees. 
It is also possible that individuals with existing drug dependence issues were more likely to 
have been continuously insured, being motivated to maintain their prescribed treatment 
regimens. 
 
In addition to being more likely to be diagnosed with OUD, the continuously insured, if 
diagnosed, were more likely to receive MAT, possibly due to having had access to addiction 
treatment resources for longer. With greater access to care, these patients likely had more 
opportunities to initiate MAT. The length of the study period (24 months) may not have been 
sufficient to see comparable access to MAT among newly and returning insured enrollees. 
Additionally, there is evidence of a gap between treatment demand and MAT capacity, which 
may have impacted the newly and returning insured more than the continuously insured38. 
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This study had limitations. Claims data did not capture self-paid prescriptions or opioids 
obtained through diversion. Although we adjusted for comorbidity level and chronic pain 
type, we were not able to measure the severity of pain experienced by patients. We were 
unable to determine an initial date of diagnosis for a small percent of patients with MAT 
before OUD diagnosis (3.6% of the sample with OUD). We were also unable to assess 
continuity of care by insurance status, which could impact OUD diagnosis and MAT receipt. 
Importantly, our data was limited to Oregon Medicaid claims and enrollment files, so we do 
not know if newly and returning Medicaid enrollees had other insurance (e.g. private 
insurance or Medicaid from another state) before 2014. Our exclusion of patients with cancer 
diagnosis (other than non-malignant skin cancer) may have removed cancer survivors who 
are not in active treatment. Our data did not have information on cancer stage and thus we 
were unable to identify these potential survivors to include in our analyses. Additionally, we 
were unable to identify enrollees who died and this may have contributed to beneficiaries 
with any coverage gaps during the study period being excluded; however, in our examination 
of enrollees with a diagnosis code indicating opioid overdose (unknown if fatal or non-fatal), 
we observed that less than half of a percent of patients with any prescribed opioid use 
experienced an overdose event. Because this percent was low and similar between insurance 
groups, potential for selection bias is minimal. Finally, our sample was limited to Oregon 




Medicaid plays an important role in fighting the opioid epidemic: for low-income individuals 
who struggle with addiction, it is often the only affordable option for getting appropriate 
treatment. Opioid use in newly and returning insured enrollees after the ACA Medicaid 
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expansion was lower than in the continuously insured, possibly reflecting lower prescribing 
rates combined with difficulties in discontinuing opioids in long-term users with more stable 
insurance coverage; however, prescribing remains high. Lower likelihood of MAT among 
newly and returning insured patients with OUD relative to continuously insured patients with 
OUD suggests that newly eligible enrollees may not yet have established the continuity of 
care often needed for MAT; alternately, they may have prioritized competing healthcare 
needs. It is essential, therefore, that policymakers consider the importance of Medicaid 
continuity and primary care continuity in combating the opioid epidemic and that they 
continue to provide adequate access to continuous insurance. 
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Table 1: Characteristics of newly, returning, and continuously insured enrollees (full sample). 


















Total N | ESS 108,501 59,811 56,983 
 
86,957 47,259 34,863  
Age group         
19-29  23.3  31.6  32.4  0.1942  27.8   27.8   27.7  0.0033 
30-39  22.2  26.0  29.3  0.1582  25.0   25.0   25.0  0.0005 
40-64  54.5  42.4  38.4  0.3286 47.3  47.2  47.4  0.0036 
Female  44.4  53.9  67.9  0.4827 52.8  53.0  53.0  0.0048 
Race/Ethnicity    
 
    
Hispanic  16.0   14.7   9.0  0.218  13.9   13.9   13.8  0.0033 
Non-Hisp. Non-White   8.8   9.7   8.7  0.0342 9.1   9.1   9.0  0.0022 
Non-Hisp. White  51.9  69.6  75.5  0.5274 62.6  63.0  63.2  0.0148 
Non-Hisp. Unknown  23.3   6.0   6.8  0.7061  14.5   14.0   13.9  0.0218 
Rural Setting2  36.4  41.5  41.7  0.106  39.2   39.2   39.4  0.0042 
ZCTA3 Unemployment %         
0-8.09  29.5  21.9  20.5  0.2204  25.2   24.9   24.7  0.011 
8.09-9.58  25.5  24.2  24.0  0.035  24.8   24.9   24.8  0.0029 
9.58-11.56  23.2  26.4  27.3  0.093  25.1   25.2  25.3  0.0037 
11.56-38.84  21.7  27.4  28.1  0.1435  24.8   24.9  25.1  0.0068 
Unknown     0.1     0.1     0.0  0.0186    0.1     0.1     0.1  0.0088 
ZCTA3 Poverty %         
0-13.0  27.9  22.4  22.4  0.1321  25.1   25.0   25.0  0.002 
13.0-17.0  26.4  25.1  23.8  0.0607  25.3   25.1   25.1  0.0044 
17.0-22.6  23.9  26.3  27.6  0.0814  25.4   25.5   25.5  0.0025 
22.6-100  21.8  26.2  26.3  0.1033  24.1   24.3   24.3  0.0043 
Unknown     0.1     0.1     0.0  0.0206    0.1     0.1     0.0  0.0096 
Co-Morbidity Index4          
0  45.5  37.1  31.0  0.3052  39.6   39.4   39.3  0.0061 
1 to 2  20.4  17.4  20.9  0.0885  19.7   19.7   19.7  0.0019 
3 to 4  19.3  25.2  24.9  0.1351  22.2   22.4   22.4  0.0046 
5 to 6   9.2   12.4   13.5  0.1279  11.1   11.2   11.2  0.0014 
7+   5.7   7.9   9.8  0.1422  7.4   7.4   7.4  0.0012 
Migraine   4.6   6.8   10.7  0.2422  6.8   6.8   6.8  0.0014 
Joint Pain  36.5  42.1  49.0  0.2533  41.2   41.3  41.4  0.0041 
Osteoarthritis   8.8   8.6   10.0  0.0499   9.1   9.1  9.1  0.0011 
Back Pain  24.6  30.6  38.5  0.306  29.7   29.9   29.8  0.0048 
General Chronic Pain   8.4   11.1  15.8  0.2363 11.2   11.1  11.2  0.0021 
1 Maximum absolute standardized mean difference (ASMD) across all pairwise comparisons for each level of pretreatment covariate. 
2 Rural defined by zip codes ten or more miles from the centroid of a population center of 40,000 people or more (Oregon Office of Rural 
Health). 
3 ZIP Code Tabulation Areas. 
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Table 2: Inverse-Probability of Treatment Weighted Sample Adjusted Regression Results 
 





% Patients with any 
opioid dispensed1 (full 
sample) 
Newly insured  42.3% 42.0-42.7% 
Returning insured 49.3% 48.8-49.7% 
Continuously insured 52.5% 52.0-53.0% 
% Patients with chronic 
opioid use1 (sample with 
any opioid dispensed) 
Newly insured Number of 
episodes 
12.8% 12.4-13.1% 
Returning insured 11.9% 11.5-12.3% 
Continuously insured 15.8% 15.4-16.2% 
% Patients with OUD 
diagnosis1 (full sample) 
Newly insured  3.6% 3.4-3.7% 
Returning insured 3.9% 3.8-4.1% 
Continuously insured 4.7% 4.5-4.9% 
Hazard Ratio, MAT 
receipt (sample with 
OUD diagnosis) 
Newly insured (REF: Continuously 
insured) 
 0.57 0.53-0.61 
Returning insured (REF: 
Continuously insured) 
0.60 0.56-0.65 
Odds Ratio, OUD 
diagnosis1 (sample with 
any opioid dispensed) 






Returning insured (REF: 
Continuously insured) 
0.91 0.85-0.98 
Note: These are a selected sample of regression results. See Appendix D for all regression results. 
1Results from an IPT-weighted binary logistic regression model 
2Results from an IPT-weighted Cox proportional hazards model 
CI = confidence interval 
OUD = opioid-use-disorder 
MAT = medication-assisted treatment  
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Figure 1: Percent of any opioid prescribing in the overall sample and percent of low dose chronic use, 
medium dose chronic use, high dose non-chronic use, and high dose chronic use among patients with 





Chronic low: 1-30 average daily MME, >90 days 
Chronic medium: 31-90 average daily MME, >90 days 
Chronic high: >90 average daily MME, >90 days 
Non-chronic high: >90 average daily MME, ≤90 days 
 
Opioids prescribed in our sample included butorphanol, codeine, fentanyl, hydrocodone, 
hydromorphone, levorphanol, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, 
pentazocine, tapentadol, and tramadol. 
 
Horizontal bars indicate 95% confidence intervals for likelihood of any opioid prescription; vertical 
bars indicate 95% confidence intervals chronic low, chronic medium, and chronic high opioid use. 
These estimates and confidence intervals were produced using binary and multinomial logistic models 
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IPT = inverse-probability of treatment 
OUD = opioid-use-disorder 
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Figure 3: Percent of opioid-use-disorder diagnosis by episode type and insurance group among 
patients with any opioid prescription 





1: Non-chronic (≤90 day) use and no high (>90 daily MME) dose, N=86,349 
2: Low (1-30 daily MME) dose chronic (>90 day) use and no high dose, N=6,649 
3: Non-chronic or low dose chronic use and at least one high dose, N=4,648 
4: Medium (31-90 daily MME) chronic use and no high dose, N=5,207 
5: Medium or high dose chronic use and at least one high dose, N=2,178 
 
These estimates and 95% confidence intervals were produced using binary logistic models 
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Appendix for 
“Prescription Opioid Use Patterns, Use Disorder Diagnoses, and Addiction Treatment 
Receipt after the 2014 Medicaid Expansion in Oregon” 
 
The Appendix material contains 4 sections: 
Appendix Exhibit A: Sample Exclusions 
Appendix Exhibits B1-B4: Definitions 
Appendix Exhibit B1: Definition of opioid use disorder (OUD) diagnosis. 
Appendix Exhibit B2: Definition of receipt of medication-assisted treatment (MAT) 
services. 
Appendix Exhibit B3: Chronic pain diagnoses. 
Appendix Exhibit B4: Definition of opioid overdose event. 
Appendix Exhibits C1-C2: Covariate Balance Tables 
Appendix Exhibit C1: Characteristics of newly, returning, and continuously insured 
enrollees (sample with any opioid dispensed). 
 
Appendix Exhibit C2: Characteristics of newly, returning and continuously insured 
enrollees (sample with OUD diagnosis). 
Appendix Exhibits D1-D7: Covariate-Adjusted Parameter Estimates 
Appendix Exhibit D1: Binary logistic regression with inverse-probability of treatment 
weights (IPTW). Marginal predicted probabilities for any opioid prescription filled 
(full sample) by insurance group. 
Appendix Exhibit D2: Binary logistic regression with IPTW. Marginal predicted 
probabilities for any chronic episode (sample with any opioid dispensed) by insurance 
group. 
 
Appendix Exhibit D3: Multinomial logistic regression with IPTW. Marginal predicted 
probabilities for level of chronic opioid use (sample with any opioid dispensed) by 
insurance group. 
Appendix Exhibit D4: Binary logistic regression with IPTW. Marginal predicted 
probabilities for diagnosis of OUD (full sample) by insurance group. 
Appendix Exhibit D5: Cox regression with IPTW. Time to receipt of MAT services 
after OUD diagnosis by insurance group (sample with OUD diagnosis, excluding 
patients with MAT receipt before OUD diagnosis). 
 
Appendix Exhibit D6: Binary logistic regression with IPTW. Marginal predicted 
probabilities for diagnosis of OUD (sample with any opioid dispensed) by insurance 
group and episode type. 
 
Appendix Exhibit D7: Binary logistic regression with IPTW. Odds ratios for 
diagnosis of OUD by insurance group (sample with any opioid dispensed).  
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Appendix Exhibit A: Sample Exclusions 
 
Adult patients with any Medicaid enrollment in 2014 (n=622,513) 
Exclusion Criteria Frequency Percent 
No coverage on 1/1/2014 97,005 15.6 
Other Coverage Gap in Study Period 167,779 27.0 
Incomplete data due to dual Medicaid/Medicare coverage 28,196 4.5 
Eligibility based on pregnancy 13,376 2.1 
Eligibility based on disability 37,584 6.0 
Eligibility based on programs not tied to Medicaid 
Expansion (e.g. TANF, former Foster Care children, dialysis 
patients) 
23,409 3.8 
Partial Coverage in 2013* 





Study Enrollees 225,295 36.2 
*Patients with partial coverage in 2013 were not eligible for the continuously insured group, 
which required full coverage in 2013, or the newly or continuously insured groups, which 
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Appendix Exhibits B1-B4: Definitions 
 
Appendix Exhibit B1: Definition of opioid use disorder (OUD) diagnosis. 
This is a binary variable indicating whether a subject had a documented diagnosis of OUD 
during the study period. Classification was based on any of the following ICD-9 or ICD-10 
diagnosis codes being present in any claims. 
ICD-9: 304.00, 304.01, 304.02, 305.50, 305.51, 305.52. 
ICD-10: F11.20, F11.222, F11.259, F11.281, F11.282, F11.288, F11.10, F11.159, 
F11.181, F11.182, F11.188. 
 
Appendix Exhibit B2: Definition of receipt of medication-assisted treatment (MAT) services. 
This is a binary variable indicating any claims with any of the following procedure codes or 
National Drug Codes (NDC). 
Procedure Codes 
H0020, H0033 with HF or HG modifier, H0016, T1502 with HF or HG modifier, 
J0571-J0575. 
NDCs 
Buprenorphine HCl: 00054017613, 00054017713, 00054018813, 00054018913, 
00093537856, 00093537956, 00228315303, 00228315603, 00378092393, 
00378092493, 50383092493, 50383093093 
Buprenorphine-Naloxone: 00228315403, 00228315473, 00228315503, 
00228315573, 00093572056, 00093572156, 12496120203, 12496120403, 
12496120803, 12496121203, 42291017530, 50383028793, 50383029493, 
65162041503, 65162041603  
Methylnaltrexone Bromide: 65649055102, 65649055103, 65649055107, 
65649055204  
Note: Methadone administered for treatment of OUD was paid using CPT codes; thus 
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Appendix Exhibit B3: Chronic pain diagnoses. 
Category Diagnoses included ICD-9 
codes 
ICD-10 codes 
Migraine Migraine 346 G43 
Joint pain Diffuse diseases of connective 
tissue; arthropathies; rheumatoid 
arthritis and other inflammatory 
polyarthropathies; polymyalgia 
rheumatica; peripheral 
enthesopathies; other disorders 
of synovium, tendon, and bursa; 
disorders of muscle, ligament, 












Osteoarthritis Osteoarthritis and allied 
disorders; ankylosing 
spondylitis and other 
inflammatory spondylopathies. 
715, 720 M15-M19, M45-
M46 
Back and spinal pain Spondylosis and allied 
disorders; intervertebral disc 
disorders; other disorders of 
cervical region; other and 
unspecified disorders of back. 




Tension headache; other pain 
disorders related to 
psychological factors; chronic 
pain due to trauma; chronic 
post-thoracotomy pain; other 
chronic postoperative pain; 
















This article is protected by copyright. All rights reserved. 
Appendix Exhibit B4: Definition of opioid overdose event. 
 Contributing cause 
(ICD-10) 





T400 (Poisoning by 
Opium), T401 
(Poisoning by Heroin), 
T402 (Poisoning by 











(Poisoning by Other 
Opiates) 
E8500 (Accidental 





by Other Opiates)  
 
These codes (ICD-10 Contributing Cause or ICD-9 Diagnosis or External Cause of Injury) 
capture both 1) non-fatal overdoses resulting in hospitalization or other medical care and 2) 
fatal overdoses resulting in hospitalization or other medical care.  
Below is a table of raw (unadjusted) counts for patients with ≥1 opioid overdose event for all 
three samples by insurance group. 
 Full sample Sample with any 
opioid 
Sample with OUD 
diagnosis 
Insurance Group N  N (%) 
opioid 
overdose 
N  N (%) 
opioid 
overdose 
N  N (%) 
opioid 
overdose 
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Appendix Exhibits C1-C2: Covariate Balance Tables 
Appendix Exhibit C1: Characteristics of newly, returning and continuously insured enrollees 
(sample with any opioid dispensed). 


















Total N | ESS 40,614 30,164 34,253 
 
31,332 27,607 25,832  
Age group         
19-29  17.8   27.9  30.7  0.2828  24.8   24.9   24.9  0.0022 
30-39  21.7   26.8  30.4  0.1939  26.0   26.0   26.0  0.0012 
40-64 60.5  45.2  38.9  0.439  49.2   49.1   49.1  0.0031 
Female 46.7  57.1  71.5  0.5188  57.6   57.8   57.9  0.0059 
Race/Ethnicity    
 
    
Hispanic  13.6   12.0   7.5  0.2092  11.1   11.2   11.1  0.0008 
Non-Hisp. Non-White  8.3   9.2   7.9  0.0468   8.4    8.4    8.3  0.0042 
Non-Hisp. White 60.3  72.8  77.7  0.4042  69.7   69.8   70.1  0.0093 
Non-Hisp. Unknown  17.8   6.0   7.0  0.4757  10.8   10.6   10.5  0.0115 
Rural setting2 40.1  42.7  42.2  0.0533  41.5   41.5   41.5  0.0007 
ZCTA3 Unemployment %         
0-8.09 26.2   21.2   20.1  0.1521  22.8   22.7   22.6  0.0048 
8.09-9.58 24.7   23.7   23.5  0.0278  24.1   24.1   24.0  0.0031 
9.58-11.56 25.1   26.8   27.9  0.0628  26.5   26.5   26.6  0.0022 
11.56-38.84  23.8   28.2   28.4  0.1014  26.6   26.5   26.8  0.0057 
Unknown    0.1     0.1     0.1  0.014     0.1      0.1      0.0  0.0084 
ZCTA3 Poverty %         
0-13.0 26.5   22.2   22.3  0.1026  24.0   24.0   23.8  0.0039 
13.0-17.0 25.6   25.0   24.0  0.0376  24.8   24.8   24.8  0.0005 
17.0-22.6 25.8   26.9   28.1  0.0505  26.8   26.9   26.9  0.0026 
22.6-100  22.0   25.8   25.7  0.0854  24.4   24.3   24.4  0.0018 
Unknown    0.1     0.1     0.0  0.0174     0.1      0.1      0.0  0.0074 
Co-Morbidity Index4          
0  23.9   21.5   19.6  0.1073  21.8   21.8   21.8  0.0023 
1 to 2  22.2   17.6   20.3  0.1151  20.2   20.3   20.3  0.0025 
3 to 4 26.9   30.5   28.9  0.0798  28.5   28.6   28.6  0.002 
5 to 6  15.7   17.6   17.5  0.0484  16.8   16.8   16.8  0.0015 
7+  11.4   12.8   13.7  0.0693  12.6   12.6   12.5  0.0018 
Migraine  8.0   10.1   14.3  0.2041  10.7   10.6   10.7  0.0012 
Joint Pain 58.9  59.4  62.1  0.0668  60.2   60.1   60.1  0.0033 
Osteoarthritis  17.0   13.7   14.2  0.0918 15.1   15.0   15.0  0.0022 
Back Pain 43.8  45.8  51.6  0.1560  46.8   46.9   46.9  0.0025 
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General Chronic Pain  17.9   18.7   23.2  0.1345  20.0   19.8   20.0  0.0033 
 
1 Maximum absolute standardized mean difference (ASMD) across all pairwise comparisons for each level of 
pretreatment covariate. 
2 Rural defined by zip codes ten or more miles from the centroid of a population center of 40,000 people or 
more (Oregon Office of Rural Health). 
3 ZIP Code Tabulation Areas. 
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Appendix Exhibit C2: Characteristics of newly, returning and continuously insured enrollees 
(sample with OUD diagnosis). 
 


















Total N | ESS 2,941 2,673 3,343 
 
2,327 2,515 2,550  
Age group         
19-29 36.0   36.7   28.4  0.176 33.7  33.5  32.9  0.0176 
30-39  27.9   27.9  37.1  0.1953 31.0  31.0  31.7  0.0135 
40-64 36.1   35.4  34.5  0.0346 35.2  35.4  35.4  0.0041 
Female  32.2  44.8  66.9  0.702 48.0  48.9  49.7  0.0327 
Race/Ethnicity    
 
    
Hispanic  10.7   9.2   3.8  0.2854  7.7   7.6   7.0  0.0264 
Non-Hisp. Non-White  6.5   8.1   6.0  0.0814  6.7   6.8   6.6  0.0082 
Non-Hisp. White 68.0  76.8  82.3  0.357 76.3  76.7  77.7  0.0334 
Non-Hisp. Unknown  14.8   6.0   7.8  0.3448  9.3   9.0   8.7  0.0229 
Rural setting2  28.6   30.4  30.7  0.0456 29.8  30.0  29.8  0.0047 
ZCTA3 Unemployment %         
0-8.09  27.2   21.5   20.7  0.1603 23.3  23.0  22.5  0.0206 
8.09-9.58  26.9   27.0   25.3  0.0388 26.4  26.5  26.7  0.0073 
9.58-11.56  25.5   26.5   27.3  0.0409 26.6  26.3  26.4  0.0057 
11.56-38.84  20.3   24.7   26.5  0.1421 23.5  23.9  24.2  0.0158 
Unknown    0.2     0.3     0.3  0.0243   0.3    0.3    0.3  0.0031 
ZCTA3 Poverty %         
0-13.0  28.2   24.7   23.0  0.1225 25.2  25.4  25.2  0.0046 
13.0-17.0  24.5   22.7   20.8  0.0889 22.5  22.7  22.3  0.0099 
17.0-22.6  25.6   25.7   28.3  0.0599 26.6  26.5  26.5  0.0043 
22.6-100  21.5   26.5   27.7  0.1382 25.4  25.2  25.9  0.0146 
Unknown    0.2     0.3     0.3  0.0243   0.3    0.3    0.3  0.0031 
Co-Morbidity Index4          
0   0.5     0.2     0.1  0.0885   0.3    0.2    0.3  0.023 
1 to 2   0.4     0.3     0.1  0.0483   0.2    0.2     0.1  0.0328 
3 to 4 44.7  41.4  40.8  0.0789 42.4  42.5  42.4  0.0019 
5 to 6  29.6   31.0   29.5  0.0323 29.6  29.9  29.9  0.0064 
7+  24.8   27.1   29.4  0.1025 27.5  27.2  27.4  0.0062 
Migraine  6.8   9.9   13.6  0.2234  9.9   10.0   10.4  0.0162 
Joint Pain 52.8  58.0  60.6  0.1583 57.2  57.2  56.8  0.0097 
Osteoarthritis  12.6   12.3   14.1  0.052 13.0  12.7  13.0  0.0096 
Back Pain 42.9  45.1  53.9  0.2188 47.1  47.3  47.9  0.0163 
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General Chronic Pain  28.7   27.8  35.1  0.1592 30.8  30.4  30.9  0.0101 
 
1 Maximum absolute standardized mean difference (ASMD) across all pairwise comparisons for each level of 
pretreatment covariate. 
2 Rural defined by zip codes ten or more miles from the centroid of a population center of 40,000 people or 
more (Oregon Office of Rural Health). 
3 ZIP Code Tabulation Areas. 
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Appendix Exhibits D1-D8: Covariate-Adjusted Parameter Estimates 
 
Appendix Exhibit D1: Binary logistic regression with IPTW. Marginal predicted probabilities 
for any opioid prescription filled (full sample) by insurance group.  
Number of observations: 225,295 
Dependent variable: Any opioid prescription filled 
Independent variable: Insurance group 
Adjusted predictions 
Insurance group Estimate Standard Error 95% Confidence Interval 
Newly insured 0.4234 0.0017 0.4200-0.4267 
Returning insured 0.4925 0.0023 0.4880-0.4970 
Continuously insured 0.5250 0.0027 0.5197-0.5303 
 
 
Appendix Exhibit D2: Binary logistic regression with IPTW. Marginal predicted probabilities 
for any chronic episode (sample with any opioid dispensed) by insurance group. 
Number of observations: 105,031 
Dependent variable: Any chronic episode 
Independent variable: Insurance group 
Additional covariate: Number of episodes 
Adjusted predictions 
Insurance group Estimate Standard Error 95% Confidence Interval 
Newly insured 0.1276 0.0019 0.1240-0.1313 
Returning insured 0.1190 0.0019 0.1152-0.1227 
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Appendix Exhibit D3: Multinomial logistic regression with IPTW. Marginal predicted 
probabilities for level of chronic opioid use (sample with any opioid dispensed) by insurance 
group.  
Number of observations: 105,031 
Dependent variable: Level of chronic opioid use (no chronic and low/medium acute, no 
chronic and high acute, low chronic, medium chronic, and high chronic) 
Independent variables: Insurance group 
Additional covariate: Number of episodes 
Adjusted predictions 






Newly insured No chronic, 
low/medium acute (≤90 
MME) 0.8265 0.0021 0.8224-0.8306 
Returning insured No chronic, 
low/medium acute (≤90 
MME) 0.8411 0.0022 0.8369-0.8453 
Continuously insured No chronic, 
low/medium acute (≤90 
MME) 0.8004 0.0023 0.7959-0.8050 
Newly insured No chronic, high acute 
(>90 MME) 0.0459 0.0012 0.0435-0.0482 
Returning insured No chronic, high acute 
(>90 MME) 0.0399 0.0012 0.0376-0.0422 
Continuously insured No chronic, high acute 
(>90 MME) 0.0415 0.0012 0.0390-0.0439 
Newly insured Low chronic 
(1-30 MME) 0.0633 0.0014 0.0605-0.0660 
Returning insured Low chronic 
(1-30 MME) 0.0590 0.0014 0.0563-0.0618 
Continuously insured Low chronic 
(1-30 MME) 0.0719 0.0015 0.0690-0.0748 
Newly insured Medium chronic (31-90 
MME) 0.0477 0.0012 0.0453-0.0501 
Returning insured Medium chronic (31-90 
MME) 0.0459 0.0013 0.0434-0.0484 
Continuously insured Medium chronic (31-90 
MME) 0.0626 0.0014 0.0598-0.0653 
Newly insured High chronic (>90 
MME) 0.0167 0.0007 0.0153-0.0181 
Returning insured High chronic (>90 
MME) 0.0141 0.0007 0.0127-0.0154 
Continuously insured High chronic (>90 
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Appendix Exhibit D4: Binary logistic regression with IPTW. Marginal predicted probabilities 
for diagnosis of OUD (full sample) by insurance group.  
Number of observations: 225,295 
Dependent variable: Diagnosis of OUD 
Independent variable: Insurance group 
Adjusted predictions 
Insurance group Estimate Standard Error 95% Confidence Interval 
Newly insured 0.0356 0.0007 0.0342-0.0370 
Returning insured 0.0392 0.0008 0.0377-0.0407 
Continuously insured 0.0470 0.0009 0.0452-0.0489 
 
 
Appendix Exhibit D5: Cox Regression with IPTW. Time to receipt of MAT services after 
OUD diagnosis by insurance group (sample with OUD diagnosis, excluding patients with 
MAT receipt before OUD diagnosis). 
164 (3.7%) of 4,446 patients who received MAT did not have any diagnosis of OUD during 
the study period. Because we were unable to determine when, if ever, they were diagnosed 
with OUD, these patients were not included in the time-to-event analysis. 
320 (3.6%) of 8,957 patients diagnosed with OUD in our sample received MAT before their 
earliest known diagnoses of OUD. These patients were excluded from the time to event 
analysis. In the weighted sample of patients with OUD, 2.9% of the newly insured, 2.5% of 
the returning insured, and 5.1% of the continuously insured were excluded from the MAT 
analysis for this reason. 
Number of observations: 8,637 
Dependent variable: Time from OUD diagnosis to MAT receipt 
Independent variable: Insurance group 
 
Adjusted hazard ratio estimates 
Insurance group Estimate Standard Error 95% Confidence Interval 
Newly insured (REF: 
Continuously insured) 
0.5711 0.0222 0.5292-0.6163 
Returning insured (REF: 
Continuously insured 
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Appendix Exhibit D6: Binary logistic regression with IPTW. Marginal predicted probabilities 
for diagnosis of OUD (sample with any opioid dispensed) by insurance group and episode 
type. 
Number of observations: 105,031 
Dependent variable: Diagnosis of OUD 
Independent variables: Insurance group, episode type 
Additional covariate: Number of episodes 
Episode type: 
1: No chronic opioid use and no high dose episode 
2: Low chronic opioid use and no high dose episode 
3: No chronic or low chronic opioid use; ≥1 high dose episode 
4: Medium chronic use and no high dose episode 




Insurance group/Episode type Estimate Standard Error 95% Confidence 
Interval 
Newly insured / 1 0.0431 0.0012 0.04076-0.0454 
Returning insured / 1 0.0460 0.0012 0.04368-0.04823 
Continuously insured / 1 0.0500 0.0013 0.04755-0.05254 
Newly insured / 2 0.0671 0.0035 0.06016-0.07398 
Returning insured / 2 0.0714 0.0037 0.06417-0.07866 
Continuously insured / 2 0.0776 0.0038 0.07013-0.08507 
Newly insured / 3 0.0874 0.0048 0.07791-0.0968 
Returning insured / 3 0.0929 0.0051 0.0830-0.1028 
Continuously insured / 3 0.1007 0.0054 0.0901-0.1113 
Newly insured / 4 0.1265 0.0056 0.1156-0.1374 
Returning insured / 4 0.1341 0.0058 0.1229-0.1454 
Continuously insured / 4 0.1449 0.0057 0.1337-0.1561 
Newly insured / 5 0.2506 0.0108 0.2295-0.2717 
Returning insured / 5 0.2634 0.0111 0.2417-0.2851 
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Appendix Exhibit D7: Binary logistic regression with IPTW. Odds ratios for diagnosis of 
OUD (sample with any opioid dispensed) by insurance group. 
Number of observations: 105,031 
Dependent variable: Diagnosis of OUD 
Independent variable: Insurance group 
Additional covariates: Episode type, number of episodes 
 
Adjusted Odds Ratios 
Insurance group Estimate Standard Error 95% Confidence Interval 
Newly insured (REF: 
Continuously insured) 
0.8544 0.0310 0.7957-0.9175 
Returning insured (REF: 
Continuously insured 
0.9141 0.0318 0.8538-0.9785 
 
 
Appendix Exhibit D8: Binary logistic regression with IPTW. Marginal predicted probabilities 
for any opioid overdose event, fatal or non-fatal, resulting in hospitalization or visit (full 
sample) by insurance status. 
Number of observations: 225,295 
Dependent variable: Any opioid overdose event. 
Independent variable: Insurance group. 
Adjusted predictions 
Insurance group Estimate Standard Error 95% Confidence Interval 
Newly insured 0.0031 0.0002 0.0027-0.0035 
Returning insured 0.0032 0.0002 0.0024-0.0036 
Continuously insured 0.0019 0.0002 0.0016-0.0023 
 
 
